Heart Disease Clinical Trials in Cleveland

Showing 421-440 of 448 trials

NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

NCT00293137

The principal aim is to investigate the safety and efficacy of rosiglitazone in patients with chronic systolic heart (Dilated cardiomyopathy). We hypothesize that in patients with heart failure, rosiglitazone is safe, and can reduce nitric oxide (NO) derived oxidative stress (in particular, nitrotyrosine) thereby improving endothelial dysfunction, left ventricular performance, and metabolic parameters.

Chronic Systolic Heart Failure (Dilated Cardiomyopathy)

The Cleveland Clinic60 participantsStarted Feb 2006

Cleveland, Ohio, United States

COMPLETED< 1 mile

Biomarkers in Acute Heart Failure

NCT00537628

Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.

Shortness of BreathHeart Failure

Brahms AG1,641 participantsStarted Mar 2007

San Diego, California, United States • San Diego, California, United States • San Francisco, California, United States +12 more locations

TERMINATEDPhase 3< 1 mile

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

NCT00584896

The purpose of this study is to determine if the use of PB127 with cardiac ultrasound assists in the diagnosis or exclusion of coronary artery disease.

Coronary Artery Disease

Point Biomedical1,000 participantsStarted Oct 2007

Tucson, Arizona, United States • Burlingame, California, United States • Long Beach, California, United States +37 more locations

NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

Biomarkers in Acute Heart Failure

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent for Diagnosis of Coronary Artery Disease

Heart Disease Trials in Other Cities

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)

InSync Implantable Cardioverter Defibrillator Registry: Cardiac Resynchronization Therapy

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)

Attain StarFix™ Model 4195 Left Ventricular Lead

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).

D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

Other Conditions in Cleveland